Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q3 2016 (Next →)

Filing Date: Nov 14, 2016

Total Value ($000): $365,999 (100.0% shares, 0.0% debt)

Holdings (7)

— SERES THERAPEUTICS INC 42.6%

Value ($000) $155,873 Shares 12,682,876 Est. Cost $12.29 Unrealized —

— SYROS PHARMACEUTICALS INC 18.2%

Value ($000) $66,668 Shares 4,806,656 Est. Cost $13.87 Unrealized —

AGIO AGIOS PHARMACEUTICALS INC 13.9%

Value ($000) $50,991 Shares 965,369 Est. Cost $43.55 Unrealized 0.0%

EDIT EDITAS MEDICINE INC 12.7%

Value ($000) $46,578 Shares 3,455,316 Est. Cost $20.49 Unrealized 0.0%

— SELECTA BIOSCIENCES INC 6.4%

Value ($000) $23,539 Shares 1,651,862 Est. Cost $14.25 Unrealized —

— T2 BIOSYSTEMS INC 4.3%

Value ($000) $15,756 Shares 2,176,167 Est. Cost $7.24 Unrealized —

— ELEVEN BIOTHERAPEUTICS INC 1.8%

Value ($000) $6,594 Shares 2,354,710 Est. Cost $2.80 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	SERES THERAPEUTICS INC	12,682,876	$155,873	42.6%	$12.29	—	COM	81750R102
—	SYROS PHARMACEUTICALS INC	4,806,656	$66,668	18.2%	$13.87	—	COM	87184Q107
AGIO	AGIOS PHARMACEUTICALS INC	965,369	$50,991	13.9%	$43.55	0.0%	COM	00847X104
EDIT	EDITAS MEDICINE INC	3,455,316	$46,578	12.7%	$20.49	0.0%	COM	28106W103
—	SELECTA BIOSCIENCES INC	1,651,862	$23,539	6.4%	$14.25	—	COM	816212104
—	T2 BIOSYSTEMS INC	2,176,167	$15,756	4.3%	$7.24	—	COM	89853L104
—	ELEVEN BIOTHERAPEUTICS INC	2,354,710	$6,594	1.8%	$2.80	—	COM	286221106